WO 2004/014406


Effect of 22-day Avemar-treatment (p.o.)


on adjuvant arthritis in Wistar rats

(injected foot pad)

PCT/HU2003/000065







Increase in paw volume (10-2 ml)

SUBSTITUTE SHEET (RULE 26)

Effect of 22-day Avemar-treatment (p.o.) on adjuvant arthritis in Wistar rats (non-injected foot pad)





Fig. 3

Effect of Avemar-treatment (p.o.) on adjuvant arthritis in Wistar rats on the 14th day (injected foot pad)



Control

2x2.5 g/kg/day

2x1.0 g/kg/day

2x0.25 g/kg/day


2x0.05 g/kg/day

Indomethacin

Dexamethasone

Fig. 4

Effect of Avemar-treatment (p.o.) on adjuvant arthritis in Wistar rats on the 18th day (injected foot pad)



Control

2x2.5 g/kg/day

2x1.0 g/kg/day


■ 2x0.25 g/kg/day ■₁2x0.05 g/kg/day

Indomethacin

Dexamethasone

Fig. 5

Effect of Avemar-treatment (p.o.) on adjuvant arthritis in Wistar rats on the 22nd day (injected foot pad)



Control

2x2.5 g/kg/day

2x1.0 g/kg/day


2x0.25 g/kg/day


2x0.05 g/kg/day


Indomethacin

Dexamethasone














Dexamethasone 2x0.05 g/kg/day 2x0.25 g/kg/day 2x2.5 g/kg/day 2x1.0 g/kg/day Indomethacin Control 0,05 Indom Dexa Effect of Avemar-treatment (p.o.) on the body weight of Wistar rats on the 22nd day 0,25 0, *** 2,52 Contr Body weight (g)

Figure 10



Avemar 2x0.25 g/kg/day Avemar 2x0.05 g/kg/day Avemar 2x1.0 g/kg/day Avemar 2x2.5 g/kg/day Dexamethasone Indomethacin Control Effect of 35-day Avemar-treatment (p.o.) on adjuvant arthritis in Wistar rats (injected foot pad) Figure 11 30 Induction of arthritis Time (day) 20 50lncrease in paw volume (10-2 ml)

SUBSTITUTE SHEET (RULE 26)



Dexamethasone 2x0.05 mg/kg/day Indomethacin 2x0.5 mg/kg/day Avemar 2x0.25 g/kg/day Avemar 2x0.05 g/kg/day Avemar 2x2.5 g/kg/day Avemar 2x1.0 g/kg/day Control Effect of 35-day Avemar-treatment (p.o.) Figure 12 on adjuvant arthritis in Wistar rats (non-injected foot pad) 8 Time (day) Induction of arthritis 20 90 lucrease in paw volume (10-2 ml)

SUBSTITUTE SHEET (RULE 26)

Fig. 13 Effect of Avemar-treatment (p.o.) on adjuvant arthritis in Wistar rats on the 28th day (injected foot pad)




Fig. 14 Effect of Avemar-treatment (p.o.) on adjuvant arthritis in Wistar rats on the








Fig. 15 Effect of Avemar-treatment (p.o.) on adjuvant arthritis in Wistar rats on the















Effect of Avemar-treatment (p.o.) on the

12/17






Figure 21




Figure 22





Figure 23






Figure 24




Figure 25

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

	☐ BLACK BORDERS
	☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
/	FADED TEXT OR DRAWING
	☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
	☐ SKEWED/SLANTED IMAGES
	☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
	☐ GRAY SCALE DOCUMENTS
	☐ LINES OR MARKS ON ORIGINAL DOCUMENT
	☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.